Charcoal hemoperfusion in the treatment of phenytoin overdose

Chiyo Imamura, Reiko Nishi, Souichi Uekihara, Syunichi Hayano, Masaki Otagiri

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

In the case of phenytoin, a drug that is generally highly protein bound, there is a lack of consensus on the use of charcoal hemoperfusion in cases of overdose. We performed charcoal hemoperfusion on a phenytoin-overdosed patient to assess the effectiveness of this treatment. The plasma concentrations of total and free phenytoin fell rapidly, from 40.0 μg/mL and 3.6 μg/mL to 16.2 μg/mL and 1.5 μg/mL, respectively, after 3 hours of hemoperfusion. The total phenytoin elimination half-life was 3.9 hours. The fraction of protein-bound phenytoin was constant (90.8% ± 0.5%) before, during, and after the procedure. The relations between the in vitro protein binding and adsorption of phenytoin to activated charcoal were also examined. Interestingly, bound phenytoin was found to dissociate from plasma proteins in the presence of activated charcoal and subsequently became adsorbed to the activated charcoal. Considering that phenytoin is bound to albumin with a large number of binding sites (n = 6) and a small binding constant (K = 6 x 103/tool/L), the extent of adsorption to activated charcoal may depend on the magnitude of the binding constant of the drug to plasma proteins. The current results suggest that charcoal hemoperfusion is effective for the removal of drugs that bind to plasma proteins with a low binding constant. (C) 2000 National Kidney Foundation, Inc.

Original languageEnglish
Pages (from-to)323-326
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume35
Issue number2
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Hemoperfusion
Charcoal
Phenytoin
Blood Proteins
Therapeutics
Adsorption
Pharmaceutical Preparations
Protein Binding
Half-Life
Albumins
Proteins
Binding Sites

Keywords

  • Charcoal hemoperfusion
  • Overdose
  • Phenytoin
  • Protein binding

ASJC Scopus subject areas

  • Nephrology

Cite this

Imamura, C., Nishi, R., Uekihara, S., Hayano, S., & Otagiri, M. (2000). Charcoal hemoperfusion in the treatment of phenytoin overdose. American Journal of Kidney Diseases, 35(2), 323-326.

Charcoal hemoperfusion in the treatment of phenytoin overdose. / Imamura, Chiyo; Nishi, Reiko; Uekihara, Souichi; Hayano, Syunichi; Otagiri, Masaki.

In: American Journal of Kidney Diseases, Vol. 35, No. 2, 2000, p. 323-326.

Research output: Contribution to journalArticle

Imamura, C, Nishi, R, Uekihara, S, Hayano, S & Otagiri, M 2000, 'Charcoal hemoperfusion in the treatment of phenytoin overdose', American Journal of Kidney Diseases, vol. 35, no. 2, pp. 323-326.
Imamura C, Nishi R, Uekihara S, Hayano S, Otagiri M. Charcoal hemoperfusion in the treatment of phenytoin overdose. American Journal of Kidney Diseases. 2000;35(2):323-326.
Imamura, Chiyo ; Nishi, Reiko ; Uekihara, Souichi ; Hayano, Syunichi ; Otagiri, Masaki. / Charcoal hemoperfusion in the treatment of phenytoin overdose. In: American Journal of Kidney Diseases. 2000 ; Vol. 35, No. 2. pp. 323-326.
@article{deb4c6db6afb4ea68e951f02e97477df,
title = "Charcoal hemoperfusion in the treatment of phenytoin overdose",
abstract = "In the case of phenytoin, a drug that is generally highly protein bound, there is a lack of consensus on the use of charcoal hemoperfusion in cases of overdose. We performed charcoal hemoperfusion on a phenytoin-overdosed patient to assess the effectiveness of this treatment. The plasma concentrations of total and free phenytoin fell rapidly, from 40.0 μg/mL and 3.6 μg/mL to 16.2 μg/mL and 1.5 μg/mL, respectively, after 3 hours of hemoperfusion. The total phenytoin elimination half-life was 3.9 hours. The fraction of protein-bound phenytoin was constant (90.8{\%} ± 0.5{\%}) before, during, and after the procedure. The relations between the in vitro protein binding and adsorption of phenytoin to activated charcoal were also examined. Interestingly, bound phenytoin was found to dissociate from plasma proteins in the presence of activated charcoal and subsequently became adsorbed to the activated charcoal. Considering that phenytoin is bound to albumin with a large number of binding sites (n = 6) and a small binding constant (K = 6 x 103/tool/L), the extent of adsorption to activated charcoal may depend on the magnitude of the binding constant of the drug to plasma proteins. The current results suggest that charcoal hemoperfusion is effective for the removal of drugs that bind to plasma proteins with a low binding constant. (C) 2000 National Kidney Foundation, Inc.",
keywords = "Charcoal hemoperfusion, Overdose, Phenytoin, Protein binding",
author = "Chiyo Imamura and Reiko Nishi and Souichi Uekihara and Syunichi Hayano and Masaki Otagiri",
year = "2000",
language = "English",
volume = "35",
pages = "323--326",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Charcoal hemoperfusion in the treatment of phenytoin overdose

AU - Imamura, Chiyo

AU - Nishi, Reiko

AU - Uekihara, Souichi

AU - Hayano, Syunichi

AU - Otagiri, Masaki

PY - 2000

Y1 - 2000

N2 - In the case of phenytoin, a drug that is generally highly protein bound, there is a lack of consensus on the use of charcoal hemoperfusion in cases of overdose. We performed charcoal hemoperfusion on a phenytoin-overdosed patient to assess the effectiveness of this treatment. The plasma concentrations of total and free phenytoin fell rapidly, from 40.0 μg/mL and 3.6 μg/mL to 16.2 μg/mL and 1.5 μg/mL, respectively, after 3 hours of hemoperfusion. The total phenytoin elimination half-life was 3.9 hours. The fraction of protein-bound phenytoin was constant (90.8% ± 0.5%) before, during, and after the procedure. The relations between the in vitro protein binding and adsorption of phenytoin to activated charcoal were also examined. Interestingly, bound phenytoin was found to dissociate from plasma proteins in the presence of activated charcoal and subsequently became adsorbed to the activated charcoal. Considering that phenytoin is bound to albumin with a large number of binding sites (n = 6) and a small binding constant (K = 6 x 103/tool/L), the extent of adsorption to activated charcoal may depend on the magnitude of the binding constant of the drug to plasma proteins. The current results suggest that charcoal hemoperfusion is effective for the removal of drugs that bind to plasma proteins with a low binding constant. (C) 2000 National Kidney Foundation, Inc.

AB - In the case of phenytoin, a drug that is generally highly protein bound, there is a lack of consensus on the use of charcoal hemoperfusion in cases of overdose. We performed charcoal hemoperfusion on a phenytoin-overdosed patient to assess the effectiveness of this treatment. The plasma concentrations of total and free phenytoin fell rapidly, from 40.0 μg/mL and 3.6 μg/mL to 16.2 μg/mL and 1.5 μg/mL, respectively, after 3 hours of hemoperfusion. The total phenytoin elimination half-life was 3.9 hours. The fraction of protein-bound phenytoin was constant (90.8% ± 0.5%) before, during, and after the procedure. The relations between the in vitro protein binding and adsorption of phenytoin to activated charcoal were also examined. Interestingly, bound phenytoin was found to dissociate from plasma proteins in the presence of activated charcoal and subsequently became adsorbed to the activated charcoal. Considering that phenytoin is bound to albumin with a large number of binding sites (n = 6) and a small binding constant (K = 6 x 103/tool/L), the extent of adsorption to activated charcoal may depend on the magnitude of the binding constant of the drug to plasma proteins. The current results suggest that charcoal hemoperfusion is effective for the removal of drugs that bind to plasma proteins with a low binding constant. (C) 2000 National Kidney Foundation, Inc.

KW - Charcoal hemoperfusion

KW - Overdose

KW - Phenytoin

KW - Protein binding

UR - http://www.scopus.com/inward/record.url?scp=0033958641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033958641&partnerID=8YFLogxK

M3 - Article

C2 - 10676735

AN - SCOPUS:0033958641

VL - 35

SP - 323

EP - 326

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -